AI Portfolio Summary
In 2025 Q4, STEMPOINT CAPITAL LP maintained a portfolio of 119 distinct positions. The most significant new addition to the portfolio was TWIST BIOSCIENCE COR, which now represents 2.82% of the total fund value. They heavily accumulated shares in ABIVAX SA, increasing their position by 135.6%. The fund also reduced its exposure to ROIVANT SCIENCES LTD by 77.0%.
Total Positions
119
Quarter
2025 Q4
Top Holding
ABVX (9.1%)
Top 10 Concentration
45.6%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-50 of 119
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ABVX
ABIVAX SA
|
Healthcare | 9.06% | 2.83% |
#1
10
Prev: #11
|
8.6 | 225,510 | 135.6% |
P
S
|
391,783 | $52,833,896 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SRRK
SCHOLAR ROCK HL...
|
Healthcare | 6.70% | 5.42% |
#2
1
Prev: #3
|
6.7 | 160,689 | 22.1% |
P
S
|
886,893 | $39,067,637 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CNTA
CENTESSA PHARMA...
|
Healthcare | 4.95% | 3.18% |
#3
4
Prev: #7
|
6.0 | 498,729 | 76.1% |
P
S
|
1,154,114 | $28,864,391 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SNDX
SYNDAX PHARMACE...
|
Healthcare | 4.83% | 4.21% |
#4
2
Prev: #6
|
2.9 | -26,826 | -2.0% |
P
S
|
1,339,379 | $28,140,353 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 4.19% | 0.73% |
#5
31
Prev: #36
|
5.2 | 221,738 | 171.4% |
P
S
|
351,073 | $24,417,127 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ACLX
ARCELLX INC
|
Healthcare | 3.72% | 0.19% |
#6
56
Prev: #62
|
4.5 | 321,484 | 2826.0% |
P
S
|
332,860 | $21,702,472 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ROIV
ROIVANT SCIENCE...
|
Healthcare | 3.60% | 12.72% |
#7
6
Prev: #1
|
1.4 | -3,230,489 | -77.0% |
P
S
|
966,698 | $20,977,347 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TERN
TERNS PHARMACEU...
|
Healthcare | 2.97% | 0.13% |
#8
65
Prev: #73
|
4.2 | 339,581 | 378.9% |
P
S
|
429,198 | $17,339,599 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TWST
TWIST BIOSCIENC...
|
Healthcare | 2.82% | — |
#9
Prev: #—
|
4.6 | 518,355 | no change |
NEW
|
518,355 | $16,442,221 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMVT
IMMUNOVANT INC
|
Healthcare | 2.81% | 5.13% |
#10
6
Prev: #4
|
1.1 | -944,621 | -59.4% |
P
S
|
644,959 | $16,394,858 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DYN
DYNE THERAPEUTI...
|
Healthcare | 2.80% | 1.20% |
#11
15
Prev: #26
|
4.1 | 360,588 | 76.0% |
P
S
|
835,200 | $16,336,512 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XENE
XENON PHARMACEU...
|
Healthcare | 2.68% | 1.55% |
#12
9
Prev: #21
|
4.1 | 156,310 | 81.3% |
P
S
|
348,605 | $15,624,476 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SRZN
SURROZEN INC
|
Healthcare | 2.17% | 1.84% |
#13
2
Prev: #15
|
1.4 | -93,697 | -13.1% |
P
S
|
619,766 | $12,672,108 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CELC
CELCUITY INC
|
Healthcare | 2.02% | 1.35% |
#14
9
Prev: #23
|
1.3 | -18,377 | -13.4% |
P
S
|
118,333 | $11,802,533 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLYS
MINERALYS THERA...
|
Healthcare | 1.80% | 1.20% |
#15
12
Prev: #27
|
3.7 | 131,937 | 83.4% |
P
S
|
290,049 | $10,525,878 | 2024 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MDGL
MADRIGAL PHARMA...
|
Healthcare | 1.77% | 0.75% |
#16
17
Prev: #33
|
3.7 | 9,529 | 116.1% |
P
S
|
17,736 | $10,328,382 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ADPT
ADAPTIVE BIOTEC...
|
Healthcare | 1.69% | — |
#17
Prev: #—
|
4.2 | 606,825 | no change |
NEW
|
606,825 | $9,854,838 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PALI
PALISADE BIO IN...
|
Healthcare | 1.69% | — |
#18
Prev: #—
|
4.2 | 4,192,375 | no change |
NEW
|
4,192,375 | $9,852,081 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CYTK
CYTOKINETICS IN...
|
Healthcare | 1.60% | — |
#19
Prev: #—
|
4.1 | 146,978 | no change |
NEW
|
146,978 | $9,338,982 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EWTX
EDGEWISE THERAP...
|
Healthcare | 1.54% | — |
#20
Prev: #—
|
4.1 | 360,876 | no change |
NEW
|
360,876 | $8,955,138 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DRUG
BRIGHT MINDS BI...
|
Healthcare | 1.30% | — |
#21
Prev: #—
|
4.0 | 97,340 | no change |
NEW
|
97,340 | $7,596,414 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
NKTR
NEKTAR THERAPEU...
|
Healthcare | 1.29% | 0.61% |
#22
17
Prev: #39
|
3.5 | 125,073 | 235.1% |
P
S
|
178,274 | $7,537,425 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JNJ
JOHNSON & JOHNS...
|
Healthcare | 1.24% | — |
#23
Prev: #—
|
4.0 | 35,000 | no change |
NEW
|
35,000 | $7,243,250 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DNLI
DENALI THERAPEU...
|
Healthcare | 1.19% | 5.05% |
#24
19
Prev: #5
|
0.5 | -1,315,601 | -75.8% |
P
S
|
419,058 | $6,918,648 | 2024 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AMLX
AMYLYX PHARMACE...
|
Healthcare | 1.17% | 0.75% |
#25
9
Prev: #34
|
3.5 | 288,256 | 104.1% |
P
S
|
565,140 | $6,826,891 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CLPT
CLEARPOINT NEUR...
|
Healthcare | 1.13% | 0.07% |
#26
51
Prev: #77
|
3.5 | 465,207 | 2793.9% |
P
S
|
481,858 | $6,591,817 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ARQT
ARCUTIS BIOTHER...
|
Healthcare | 1.12% | 1.56% |
#27
8
Prev: #19
|
0.4 | -187,153 | -45.4% |
P
S
|
224,740 | $6,526,450 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EYPT
EYEPOINT INC
|
Healthcare | 1.11% | — |
#28
Prev: #—
|
3.9 | 353,849 | no change |
NEW
|
353,849 | $6,464,821 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IMTX
IMMATICS N.V
|
Healthcare | 1.10% | — |
#29
Prev: #—
|
3.9 | 610,308 | no change |
NEW
|
610,308 | $6,408,234 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
OCUL
OCULAR THERAPEU...
|
Healthcare | 1.09% | 0.84% |
#30
2
Prev: #32
|
2.9 | 163,223 | 45.4% |
P
S
|
522,693 | $6,345,493 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RYTM
RHYTHM PHARMACE...
|
Healthcare | 1.08% | 1.85% |
#31
18
Prev: #13
|
0.4 | -32,529 | -35.6% |
P
S
|
58,915 | $6,306,262 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PRAX
PRAXIS PRECISIO...
|
Healthcare | 1.06% | — |
#32
Prev: #—
|
3.9 | 21,067 | no change |
NEW
|
21,067 | $6,209,288 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
APGE
APOGEE THERAPEU...
|
Healthcare | 1.04% | — |
#33
Prev: #—
|
3.9 | 80,574 | no change |
NEW
|
80,574 | $6,081,726 | 2025 Q2 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INCY
INCYTE CORP
|
Healthcare | 1.04% | 0.74% |
#34
1
Prev: #35
|
2.9 | 17,681 | 40.4% |
P
S
|
61,435 | $6,067,935 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
IDYA
IDEAYA BIOSCIEN...
|
Healthcare | 0.96% | 2.03% |
#35
23
Prev: #12
|
0.4 | -210,166 | -56.5% |
P
S
|
161,659 | $5,588,552 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ASMB
ASSEMBLY BIOSCI...
|
Healthcare | 0.91% | 0.34% |
#36
17
Prev: #53
|
3.4 | 90,598 | 137.0% |
P
S
|
156,728 | $5,330,319 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MAZE
MAZE THERAPEUTI...
|
Healthcare | 0.89% | — |
#37
Prev: #—
|
3.9 | 125,877 | no change |
NEW
|
125,877 | $5,215,084 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
PTGX
PROTAGONIST THE...
|
Healthcare | 0.89% | 0.64% |
#38
Prev: #38
|
2.9 | 11,476 | 23.9% |
P
S
|
59,430 | $5,190,616 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
LLY
ELI LILLY & CO
|
Healthcare | 0.88% | — |
#39
Prev: #—
|
3.9 | 4,759 | no change |
NEW
|
4,759 | $5,114,402 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
TRVI
TREVI THERAPEUT...
|
Healthcare | 0.86% | 0.64% |
#40
3
Prev: #37
|
2.3 | 48,847 | 13.9% |
P
S
|
399,557 | $5,002,454 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RVMD
REVOLUTION MEDI...
|
Healthcare | 0.85% | 1.73% |
#41
25
Prev: #16
|
0.3 | -123,348 | -66.5% |
P
S
|
62,032 | $4,940,849 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 0.82% | — |
#42
Prev: #—
|
3.8 | 154,320 | no change |
NEW
|
154,320 | $4,802,438 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ABUS
ARBUTUS BIOPHAR...
|
Healthcare | 0.81% | 0.19% |
#43
20
Prev: #63
|
3.3 | 781,363 | 380.4% |
P
S
|
986,751 | $4,746,272 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
MLTX
MOONLAKE IMMUNO...
|
Healthcare | 0.79% | — |
#44
Prev: #—
|
3.8 | 348,401 | no change |
NEW
|
348,401 | $4,591,925 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CTMX
CYTOMX THERAPEU...
|
Healthcare | 0.76% | — |
#45
Prev: #—
|
3.8 | 1,036,311 | no change |
NEW
|
1,036,311 | $4,414,685 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
XFOR
X4 PHARMACEUTIC...
|
Healthcare | 0.62% | 0.38% |
#46
5
Prev: #51
|
3.2 | 343,054 | 61.8% |
P
S
|
898,465 | $3,593,860 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
WHWK
WHITEHAWK THERA...
|
Healthcare | 0.61% | 0.16% |
#47
21
Prev: #68
|
3.2 | 1,034,725 | 244.0% |
P
S
|
1,458,807 | $3,530,313 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
DNTH
DIANTHUS THERAP...
|
Healthcare | 0.56% | 0.33% |
#48
6
Prev: #54
|
3.2 | 37,902 | 91.6% |
P
S
|
79,284 | $3,267,294 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ASND
ASCENDIS PHARMA...
|
Healthcare | 0.54% | 0.60% |
#49
9
Prev: #40
|
0.7 | -307 | -2.0% |
P
S
|
14,842 | $3,164,908 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RGEN
REPLIGEN CORP
|
Healthcare | 0.44% | — |
#50
Prev: #—
|
3.7 | 15,707 | no change |
NEW
|
15,707 | $2,573,749 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-50 of 119 holdings